NU NUS Nu Skin Enterprises, Inc. Loading... : Investor Sentiment and Bull/Bear Views

Author argues NUS is deep value at sub-5x trailing and sub-7x forward earnings, with revenue growth in Latin America, China, and South Korea, and expansion in Asia aided by the $250M sale of its affiliate platform. Margin expansion, share repurchases, and a new subscription platform launched earlier this month are expected to drive continued growth into 2026. Peers trade at 15-25x forward earnings, supporting a re-rating opportunity.

The author highlights NUS's cheap valuation: trailing P/E 4.49x, forward P/E 6.93x, EV/EBITDA 2.70x, and price/book 0.60x, with Q4 revenue of $364M and EPS of $0.34 beating estimates. Peers trade at 15-25x forward while NUS is under 7x with good cash flow and lower leverage after the $250M affiliate platform sale. The author sees potential value but notes execution risks, framing the question as whether the stock is undervalued or a value trap.

Nu Skin trades at 4.5x trailing and 6.9x forward earnings, 2.7x EV/EBITDA, and 0.60x tangible book despite 73-75% gross margins. The author argues cost rationalization is expanding operating margins while revenue grows in Latin America, China, and South Korea, with further Asia expansion into 2026 after the $250M sale of an affiliate platform. A new subscription platform and remaining share-repurchase authorization are additional catalysts. The valuation gap to personal care peers trading at 15-25x forward earnings supports a long.